Search results for "C2"

showing 10 items of 879 documents

A Nomogram-Based Prognostic Model for Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib: A Multicenter Study

2021

Simple Summary Accurate prognostic systems capable of predicting the survival of patients with advanced hepatocellular carcinoma undergoing Sorafenib therapy are still lacking. The search for the ideal predictive tool for survival and drug response is justified by the recent availability of several other drugs effective for these patients, licensed as first- and second-line treatment, other than reducing adverse events and costs. In this study, we aimed to identify simple demographic and clinical parameters able to predict survival and Sorafenib response in a large multicenter cohort. In this study, we showed that patient’s general status, liver function and damage laboratory parameters and…

Cohort study; Hepatocellular carcinoma; Prognosis; Sorafenib; SurvivalSorafenibOncologyCancer Researchmedicine.medical_specialtyPrognosisurvivalArticle03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicinemedicinecohort studyRC254-282Settore MED/12 - GastroenterologiaPerformance statusProportional hazards modelbusiness.industryHazard ratioNeoplasms. Tumors. Oncology. Including cancer and carcinogenshepatocellular carcinomaNomogrammedicine.diseaseOncology030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologysorafenibprognosisLiver cancerbusinessmedicine.drugCancers
researchProduct

Unexpected tumor reduction in metastatic colorectal cancer patients during SARS-Cov-2 infection: effect of ACE-2 expression on tumor cells or molecul…

2021

Colorectal cancerSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)medicine.medical_treatmentcolorectal cancermedicine.disease_causeMutually exclusive eventsMolecular oncologyMetastasismolecular oncologymedicinemetastasisprognostic biomarkerLetter to the EditorRC254-282business.industrySettore BIO/16 - Anatomia UmanaNeoplasms. Tumors. Oncology. Including cancer and carcinogensImmunotherapymedicine.diseaseMolecular mimicryOncologyTumor reductionCancer researchimmunotherapybusinesscolorectal cancer immunotherapy metastasis molecular oncology prognostic biomarker
researchProduct

Commuting powers and exterior degree of finite groups

2011

In [P. Niroomand, R. Rezaei, On the exterior degree of finite groups, Comm. Algebra 39 (2011), 335-343] it is introduced a group invariant, related to the number of elements $x$ and $y$ of a finite group $G$, such that $x \wedge y = 1_{G \wedge G}$ in the exterior square $G \wedge G$ of $G$. This number gives restrictions on the Schur multiplier of $G$ and, consequently, large classes of groups can be described. In the present paper we generalize the previous investigations on the topic, focusing on the number of elements of the form $h^m \wedge k$ of $H \wedge K$ such that $h^m \wedge k = 1_{H \wedge K}$, where $m \ge 1$ and $H$ and $K$ are arbitrary subgroups of $G$.

Combinatorics20J99 20D15 20D60 20C25General MathematicsMathematics - K-Theory and HomologyFOS: MathematicsHomological algebraK-Theory and Homology (math.KT)Invariant (mathematics)Exterior algebraMathematicsSchur multiplier
researchProduct

Dynamic-shared Pharmacophore Approach as Tool to Design New Allosteric PRC2 Inhibitors, Targeting EED Binding Pocket.

2020

Abstract: The Polycomb Repressive complex 2 (PRC2) maintains a repressive chromatin state and silences many genes, acting as methylase on histone tails. This enzyme was found overexpressed in many types of cancer. In this work, we have set up a Computer-Aided Drug Design approach based on the allosteric modulation of PRC2. In order to minimize the possible bias derived from using a single set of coordinates within the protein-ligand complex, a dynamic workflow was developed. In details, molecular dynamic was used as tool to identify the most significant ligand-protein interactions from several crystallized protein structures. The identified features were used for the creation of dynamic pha…

Computer scienceAllosteric regulationBinding pocketmacromolecular substancesComputational biologyMolecular Dynamics SimulationLigands01 natural sciences03 medical and health sciencesProtein structureStructural BiologyDrug DiscoveryHumans030304 developmental biologyEED0303 health sciencesVirtual screeningBinding SitesbiologyOrganic ChemistryMolecular DynamicPolycomb Repressive Complex 2Dynamic pharmacophorePRC20104 chemical sciencesComputer Science ApplicationsChromatinMolecular Docking Simulation010404 medicinal & biomolecular chemistryROC CurveDocking (molecular)Drug Designbiology.proteinMolecular MedicinePharmacophorePRC2Allosteric SiteProtein BindingMolecular informaticsReferences
researchProduct

A Skewed GARCH-in-Mean Model: An Application to U.S. Stock Returns

2004

In this paper we consider a GARCH-in-Mean (GARCH-M) model based on the so-called z distribution. This distribution is capable of modeling moderate skewness and kurtosis typically encountered in financial return series, and the need to allow for skewness can be readily tested. We apply the new GARCH-M model to study the relationship between risk and return in monthly postwar U.S. stock market data. Our results indicate the presence of conditional skewness in U.S. stock returns, and, in contrast to the previous literature, we show that a positive and significant relationship between return and risk can be uncovered, once an appropriate probability distribution is employed to allow for conditi…

Conditional skewness GARCH-in-Mean Risk-return tradeoffjel:C22jel:C16jel:G12
researchProduct

Accuracy and Safety of Ultrasound-Guided Core Needle Biopsy of Soft Tissue Tumors in an Outpatient Setting: A Sarcoma Center Analysis of 392 Consecut…

2021

Simple Summary In patients with unclear soft tissue lesions, treatment planning largely depends on histology. Core needle biopsy is the diagnostic standard in these cases. The aim of this retrospective study was to investigate accuracy and safety of ultrasound guided core needle biopsy at a tertiary referral center. We show that ultrasound guided biopsy was feasible as a one stop shop procedure in an outpatient setting in 87.6% of the cases. The rate of conclusive biopsies was 88.5%. After surgical resection, the dignity, tumor type and histopathological grading of the biopsy matched one of the resection specimens in 97.2%, 92.7% and 92.5% of the cases, respectively. Major complications occ…

Core needlesafetyCancer Researchmedicine.medical_specialtyConcordancecore needle biopsyArticle030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineBiopsymedicineOutpatient settingRC254-282medicine.diagnostic_testaccuracybusiness.industrySoft tissue sarcomaNeoplasms. Tumors. Oncology. Including cancer and carcinogensSoft tissuemedicine.diseaseUltrasound guided3. Good healthOncology030220 oncology & carcinogenesissoft tissue sarcomaRadiologySarcomabusinessCancers
researchProduct

Minimal unit vector fields

2002

We compute the first variation of the functional that assigns each unit vector field the volume of its image in the unit tangent bundle. It is shown that critical points are exactly those vector fields that determine a minimal immersion. We also find a necessary and sufficient condition that a vector field, defined in an open manifold, must fulfill to be minimal, and obtain a simpler equivalent condition when the vector field is Killing. The condition is fulfilled, in particular, by the characteristic vector field of a Sasakian manifold and by Hopf vector fields on spheres.

Curl (mathematics)Killing vector fieldsSolenoidal vector fieldVector operatorcritical pointsGeneral Mathematicsminimal vector fieldsMathematical analysis53C4253C20Hopf vector fields53C25Sasakian manifoldsKilling vector fieldUnit vectorFundamental vector fieldMathematics::Differential GeometryVolume of vector fieldsComplex lamellar vector fieldVector potentialMathematicsTohoku Mathematical Journal
researchProduct

Translocation of cdk2 to the nucleus during G1-phase in PDGF-stimulated human fibroblasts.

1997

We studied the subcellular distribution of cdk2 in synchronized, PDGF-stimulated human fibroblasts (FH109). After contact inhibition and serum depletion, more than 95% of FH109 cells were arrested in G0/G1-phase. PDGF-AB led to a 16-fold increase in proliferation compared with untreated cells. Cell cycle progression was studied by flow cytometric analysis, [3H]thymidine incorporation, and phosphorylation of the retinoblastoma gene product, pRB. Using Western blot analysis after subcellular fractionation, we revealed that after PDGF stimulation the phosphorylated (Thr 160), i.e., activated, form of cdk2 (33 kDa) first appeared in the nucleus at late G1-phase and persisted throughout until to…

CytoplasmFluorescent Antibody TechniqueProtein Serine-Threonine KinasesmedicineCDC2-CDC28 KinasesHumansCells CulturedCell NucleusPlatelet-Derived Growth FactorbiologyKinaseCyclin-dependent kinase 2Cyclin-Dependent Kinase 2G1 PhaseContact inhibitionBiological TransportCell BiologyCell cycleFibroblastsMolecular biologyCyclin-Dependent KinasesCell biologyCell CompartmentationCytosolmedicine.anatomical_structurebiology.proteinCell fractionationNucleusPlatelet-derived growth factor receptorCyclin-Dependent Kinase-Activating KinaseExperimental cell research
researchProduct

Molecular basis of the functional distinction between Cln1 and Cln2 cyclins

2012

Cln1 and Cln2 are very similar but not identical cyclins. In this work, we tried to describe the molecular basis of the functional distinction between Cln1 and Cln2. We constructed chimeric cyclins containing different fragments of Cln1 and Cln2 and performed several functional analysis that make it possible to distinguish between Cln1 or Cln2. We identified that region between amino acids 225 and 299 of Cln2 is not only necessary but also sufficient to confer Cln2 specific functionality compared with Cln1. We also studied Cln1 and Cln2 subcellular localization identifying additional differences between them. Both cyclins are distributed between the nucleus and the cytoplasm, but Cln1 shows…

CytoplasmSaccharomyces cerevisiae ProteinsTranscription GeneticBlotting WesternGenes FungalGenetic VectorsGreen Fluorescent ProteinsActive Transport Cell NucleusSaccharomyces cerevisiaeKaryopherinsBiologyReportCyclinsGene Expression Regulation FungalmedicineAmino Acid SequenceNuclear export signalMolecular BiologyPeptide sequenceCyclinKaryopherinCell Nucleuschemistry.chemical_classificationCell Cycle CheckpointsCell BiologySubcellular localizationCell nucleusmedicine.anatomical_structureBiochemistrychemistryCytoplasmNuclear transportCDC28 Protein Kinase S cerevisiaePlasmidsDevelopmental BiologyCell Cycle
researchProduct

Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia

2021

BackgroundT-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disease with a poor cure rate for relapsed/resistant patients. Due to the lack of T-cell restricted targetable antigens, effective immune-therapeutics are not presently available and the treatment of chemo-refractory T-ALL is still an unmet clinical need. To develop novel immune-therapy for T-ALL, we generated an afucosylated monoclonal antibody (mAb) (ahuUMG1) and two different bispecific T-cell engagers (BTCEs) against UMG1, a unique CD43-epitope highly and selectively expressed by T-ALL cells from pediatric and adult patients.MethodsUMG1 expression was assessed by immunohistochemistry (IHC) on a wide panel of normal t…

Cytotoxicity ImmunologicCancer Research2434T-LymphocytesMice SCIDafucosylated monoclonal antibodyLymphocyte ActivationPrecursor T-Cell Lymphoblastic Leukemia-LymphomaEpitopesJurkat CellsAntineoplastic Agents ImmunologicalAntibody SpecificityMice Inbred NODantigensAntibodies BispecificTumor MicroenvironmentImmunology and Allergyantibodieshematologic neoplasms1506RC254-282Antibody-dependent cell-mediated cytotoxicityLeukosialinbispecific T-cell engagersmedicine.diagnostic_testbiologyhematological malignancieNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.anatomical_structureantibodieOncologytranslational medical researchMolecular MedicineImmunohistochemistryFemaleimmunotherapyAntibodyT-ALLT-cell engagersT-cell acute lymphoblastic leukemiamedicine.drug_classT cellImmunologySettore MED/08 - Anatomia PatologicaMonoclonal antibodyAntibodies Monoclonal HumanizedFlow cytometryT Acute Lymphoblastic LeukemiaantigenAntigenPhagocytosismedicineAnimalsHumanshematological malignanciesCell ProliferationPharmacologyT-cell engagerbusiness.industryhematological malignancies; antibodies; antigens; hematologic neoplasms; immunotherapy; neoplasm; T-ALL; T-cell engagers; translational medical research; translational researchBasic Tumor ImmunologyXenograft Model Antitumor Assaystranslational researchCancer researchbiology.proteinneoplasmbusinesshematologic neoplasmneoplasm
researchProduct